|
|
Tracking and Treating Uveitic Macular Edema: A Difficult Dilemma
Uveitic macular edema (UME) has a wide variety of causes. If not appropriately treated, it eventually causes damage to the photoreceptors in the macula, resulting in vision-threatening complications like macular ischemia or macular hole formation. Corticosteroids are the first-line treatment for uveitic inflammation and UME. However, they are not generally considered to be appropriate for long-term treatment due to adverse effects, including increased intraocular pressure and cataract in local... |
|
|
Tracking and Treating Uveitic Macular Edema: A Difficult Dilemma
Uveitic macular edema (UME) has a wide variety of causes. If not appropriately treated, it eventually causes damage to the photoreceptors in the macula, resulting in vision-threatening complications like macular ischemia or macular hole formation. Corticosteroids are the first-line treatment for uveitic inflammation and UME. However, they are not generally considered to be appropriate for long-term treatment due to adverse effects, including increased intraocular pressure and cataract in local... |
|
|
A Class Act in Glaucoma Management: Differentiating Rho Kinase Inhibitors From the Pack
Medical management of glaucoma primarily focuses on lowering intraocular pressure (IOP) by decreasing aqueous production, reducing episcleral venous pressure, and/or increasing uveoscleral and trabecular outflow. Recently approved agents have expanded treatment options beyond the traditional mainstays of prostaglandin analogues and β-blockers, engaging Rho kinase (ROCK) inhibition to improve outcomes for patients with glaucoma. In this CE monograph, experts in the field will review the clinic... |
|